Patents by Inventor Aaron Lyman Sarver

Aaron Lyman Sarver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods involving endogenous retrovirus proteins
    Patent number: 9878002
    Abstract: This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: January 30, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Robyn Lynn Leary, Anindya Bagchi, Aaron Lyman Sarver
  • LYMPHOMA PROGNOSTIC METHODS AND KITS
    Publication number: 20170081726
    Abstract: This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 23, 2017
    Inventors: Jaime Freddy Modiano, Aric Mathew Frantz, Timothy David O'Brien, Aaron Lyman Sarver
  • Lymphoma prognostic methods and kits
    Patent number: 9469879
    Abstract: A method for differentiating forms of lymphoma involves analyzing a tumor tissue sample from a subject for expression of CD28, ABCA5, CCDC3, and SMOC2. The CD28:ABCA5 expression ratio differentiates T-cell tumors from B-cell tumors. The CCDC3:SMOC2 expression ratio differentiates different T-cell tumors. The method can further include administering to the subject from whom the sample was obtained an appropriate treatment for the form lymphoma identified by performing the method.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: October 18, 2016
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Jaime Freddy Modiano, Aric Mathew Frantz, Timothy David O'Brien, Aaron Lyman Sarver
  • COMPOSITIONS AND METHODS INVOLVING ENDOGENOUS RETROVIRUS PROTEINS
    Publication number: 20150352179
    Abstract: This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 10, 2015
    Inventors: Robyn Lynn Leary, Anindya Bagchi, Aaron Lyman Sarver
  • PROGNOSTIC METHODS AND KITS
    Publication number: 20150191790
    Abstract: This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.
    Type: Application
    Filed: March 12, 2013
    Publication date: July 9, 2015
    Inventors: Jaime Freddy Modiano, Aric Mathew Frantz, Timothy David O'Brien, Aaron Lyman Sarver